Serum Fibronectine in Diabetes Mellitus Type2 Diabetic Patients

Qaduwri, Safa; Kamil, Nabaa

doi:10.25673/123653

Proceedings of International Conference on Applied Innovation in IT · 2026/03/31 · Vol. 14 · Issue 1 · pp. 907–912

Serum Fibronectine in Diabetes Mellitus Type2 Diabetic Patients

Safa Fakhri Qaduwri, Nabaa H Al-Obiady and Osamah M. Kamil

📄 Download PDF DOI: 10.25673/123653

Abstract

This study investigates the role of serum fibronectin as a potential biomarker in patients with type 2 diabetes mellitus (T2DM). Fibronectin, an extracellular matrix glycoprotein, is associated with endothelial dysfunction, inflammation, and tissue remodeling, all of which are key features of diabetic complications. A case–control study was conducted including patients with T2DM and healthy control subjects. Serum fibronectin levels were measured using ELISA and analyzed in relation to biochemical parameters, including glucose, creatinine, blood urea, and glomerular filtration rate (GFR). The results demonstrated that fibronectin levels were significantly higher in T2DM patients compared to controls. In addition, fibronectin showed a strong negative correlation with GFR and positive correlations with glucose, creatinine, and blood urea levels. Receiver operating characteristic (ROC) analysis indicated that fibronectin has good diagnostic performance, with high sensitivity and specificity at the optimal cutoff value. These findings suggest that elevated fibronectin levels are associated with renal dysfunction and metabolic imbalance in T2DM.In conclusion, serum fibronectin represents a promising biomarker for early detection and monitoring of vascular and renal complications in patients with type 2 diabetes mellitus.

Keywords

Fibronectine Biomarker Disease Fibronectin Levels Diabetic Patients.

References

J. Jameson, A. Fauci, D. Kasper and S. Hauser, Harrison’s Principles of Internal Medicine, 21st ed., 2022.
M. Zhou, H. Wang, X. Zeng, P. Yin and J. Zhu, “Mortality, morbidity, and hospitalisations due to type 2 diabetes,” vol. 7, pp. 912-924, 2019.
American Diabetes Association, “Classification and diagnosis of diabetes: Standards of care in diabetes,” vol. 40, pp. S19-S40, 2024.
Y. Zheng, S. H. Ley and F. B. Hu, “Global aetiology and epidemiology of type 2 diabetes mellitus and its complications,” vol. 11, pp. 111-123, 2023.
X. Wang et al., “Cellular fibronectin promotes glomerular injury in diabetic nephropathy via integrin α5β1-mediated TGF-β1 activation,” Kidney International, vol. 101, no. 4, pp. 732-745, 2022.
Y. Liang et al., “Impaired fibronectin matrix assembly in diabetic wounds is mediated by oxidative stress and can be rescued by N-acetylcysteine,” Redox Biology, vol. 37, Art. no. 101722, 2020.
L. Sorokin and R. Fässler, “Extracellular matrix dynamics in metabolic disease: Focus on fibronectin in type 2 diabetes,” Nature Reviews Endocrinology, vol. 20, no. 2, pp. 112-127, 2024.
H. M. Alkuraishy, A. I. Al-Gareeb and H. A. Al-Hussaniy, “Fibronectin as a potential biomarker of insulin resistance and vascular complications in type 2 diabetes mellitus,” Journal of Pharmacy & Bioallied Sciences, vol. 13, Suppl. 2, pp. S112-S117, 2021.
Y. Matsushita et al., “Fibronectin deposition in the liver drives fibrosis progression in non-alcoholic steatohepatitis associated with type 2 diabetes,” Journal of Hepatology, vol. 79, no. 4, pp. 789-801, 2023.
G. Montalvo et al., “Plasma fibronectin levels in patients with type 2 diabetes: Association with insulin resistance,” Diabetes & Metabolism, vol. 41, no. 6, pp. 456-462, 2015.
K. Sakai et al., “Targeting the EDA isoform of fibronectin ameliorates insulin resistance and adipose tissue inflammation in a mouse model of type 2 diabetes,” Diabetes, vol. 71, no. 8, pp. 1725-1737, 2022.
L. Chen et al., “Fibronectin-integrin α5β1 signaling promotes IL-6 secretion from macrophages in adipose tissue of type 2 diabetic patients,” Cytokine, vol. 140, Art. no. 155602, 2021.
Z. H. Al-Hamodi et al., “Serum fibronectin levels correlate with HOMA-IR and glycemic control in type 2 diabetic patients,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 14, no. 6, pp. 1327-1432, 2020.
Y. Zhang et al., “Fibronectin-mediated endothelial dysfunction contributes to microvascular complications in type 2 diabetes,” Microvascular Research, vol. 149, Art. no. 104987, 2024.
S. Ricard-Blum and S. D. Vallet, “Matricellular proteins in type 2 diabetes: Focus on fibronectin, tenascin-C, and periostin,” Matrix Biology, vol. 126, pp. 1-18, 2024.
J. H. Lee et al., “Fibronectin enhances macrophage infiltration and M1 polarization in visceral adipose tissue of obese diabetic patients,” Immunology and Cell Biology, vol. 100, no. 5, pp. 421-433, 2022.
H. Robert and K. Richard, “Standards of medical care in diabetes,” vol. 143, pp. S1-S204, 2020.
H. Robert and M. Eckel, “Preventing cardiovascular disease and diabetes,” vol. 38, pp. 140-1449, 2015.
S. Kahn and E. Hull, “The impact of type 2 diabetes on lipoprotein metabolism,” vol. 91, pp. 837-846, 2006.
K. Maeda and Z. Anna, “Fibronectin in diabetes: A review of the literature,” vol. 9, pp. 1-9, 2018.
G. Ruan, E. Kim and N. Baqiyyah, “The role of fibronectin in the development of diabetic nephropathy,” vol. 33, pp. 538-544, 2019.
M. Khan and M. Hashim, “Type 2 diabetes: A review of the literature,” vol. 12, pp. 265-275, 2020.
American Diabetes Association, “Standards of medical care in diabetes,” vol. 43, pp. S1-S204, 2020.
Y. Zhang and X. Liu, “Fibronectin and diabetic nephropathy,” pp. 1-9, 2020.
M. Li and Y. Wang, “The role of fibronectin in diabetes,” vol. 104, pp. 5040-5048, 2019.